Kantonsspital St.Gallen
login

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

Stefan Diem, Mirjam Fässler, David Bomze, Omar Hasan Ali, Fiamma Berner, Rebekka Niederer, Dorothea Hillmann, Joanna Mangana, Mitchell P Levesque, Reinhard Dummer, Lorenz Risch, Mike Recher, Martin Risch & Lukas Flatz

abstract Checkpoint inhibitors have improved survival of metastatic melanoma. However, reliable biomarkers to predict response are still needed. Immunoglobulin G (IgG) antibody subclasses reflect immunocompetence in individuals and are known to be involved in essential functions in our immune system. This prospective study evaluated the association between serum IgG with its subclasses IgG1, IgG2, IgG3, and IgG4 and antitumor response according to RECIST 1.1. Serum samples from 49 patients were prospectively collected before the start of treatment with a checkpoint inhibitor. We observed a statistically significant association of baseline IgG2 with response to therapy (P=0.011). After defining optimal cutpoints, we found significant associations between total IgG (>9.66 g/L, P=0.038), IgG1 (>6.22 g/L, P=0.025), IgG2 (>2.42 g/L, P=0.019), and IgG3 (>0.21 g/L, P=0.034) with progression-free survival. Prolonged overall survival was associated with elevated IgG2 (>2.42 g/L, P=0.043). Together, these findings define total IgG and subclasses as predictors of clinical successful checkpoint inhibition in metastatic melanoma patients.
   
citation Diem S, Fässler M, Bomze D, Ali O H, Berner F, Niederer R, Hillmann D, Mangana J, Levesque M P, Dummer R, Risch L, Recher M, Risch M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. J Immunother 2019; 42:89-93.
   
type journal paper/review (English)
date of publishing 4-2019
journal title J Immunother (42/3)
ISSN electronic 1537-4513
pages 89-93
PubMed 30768543
DOI 10.1097/CJI.0000000000000255